Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial by Bradbury, CA, Lawler, PR, Stanworth, SJ, McVerry, BJ, McQuilten, Z, Higgins, AM, Mouncey, PR, Al-Beidh, F, Rowan, KM, Berry, LR, Lorenzi, E, Zarychanski, R, Arabi, YM, Annane, D, Beane, A, van Bentum-Puijk, W, Bhimani, Z, Bihari, S, Bonten, MJM, Brunkhorst, FM, Buzgau, A, Buxton, M, Carrier, M, Cheng, AC, Cove, M, Detry, MA, Estcourt, LJ, Fitzgerald, M, Girard, TD, Goligher, EC, Goossens, H, Haniffa, R, Hills, T, Huang, DT, Horvat, CM, Hunt, BJ, Ichihara, N, Lamontagne, F, Leavis, HL, Linstrum, KM, Litton, E, Marshall, JC, McAuley, DF, McGlothlin, A, McGuinness, SP, Middeldorp, S, Montgomery, SK, Morpeth, SC, Murthy, S

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial by Arabi, YM, Gordon, AC, Derde, LPG, Nichol, AD, Murthy, S, Beidh, FA, Annane, D, Swaidan, LA, Beane, A, Beasley, R, Berry, LR, Bhimani, Z, Bonten, MJM, Bradbury, CA, Brunkhorst, FM, Buxton, M, Buzgau, A, Cheng, A, De Jong, M, Detry, MA, Duffy, EJ, Estcourt, LJ, Fitzgerald, M, Fowler, R, Girard, TD, Goligher, EC, Goossens, H, Haniffa, R, Higgins, AM, Hills, TE, Horvat, CM, Huang, DT, King, AJ, Lamontagne, F, Lawler, PR, Lewis, R, Linstrum, K, Litton, E, Lorenzi, E, Malakouti, S, McAuley, DF, McGlothlin, A, Mcguinness, S, McVerry, BJ, Montgomery, SK, Morpeth, SC, Mouncey, PR, Orr, K, Parke, R, Parker, JC

Effect of convalescent plasma on organ support-free days in critically ill patients With COVID-19: a randomized clinical trial by Estcourt, LJ, Turgeon, AF, McQuilten, ZK, McVerry, BJ, Al-Beidh, F, Annane, D, Arabi, YM, Arnold, DM, Beane, A, Bégin, P, van Bentum-Puijk, W, Berry, LR, Bhimani, Z, Birchall, JE, Bonten, MJM, Bradbury, CA, Brunkhorst, FM, Buxton, M, Callum, JL, Chassé, M, Cheng, AC, Cove, ME, Daly, J, Derde, L, Detry, MA, De Jong, M, Evans, A, Fergusson, DA, Fish, M, Fitzgerald, M, Foley, C, Goossens, H, Gordon, AC, Gosbell, IB, Green, C, Haniffa, R, Harvala, H, Higgins, AM, Hills, TE, Hoad, VC, Horvat, C, Huang, DT, Hudson, CL, Ichihara, N, Laing, E, Lamikanra, AA, Lamontagne, F, Roberts, DJ

Long-term (180-Day) outcomes in critically ill patients with COVID-19 in the REMAP-cap randomized clinical trial by Higgins, AM, Berry, LR, Lorenzi, E, Murthy, S, McQuilten, Z, Mouncey, PR, Al-Beidh, F, Annane, D, Arabi, YM, Beane, A, van Bentum-Puijk, W, Bhimani, Z, Bonten, MJM, Bradbury, CA, Brunkhorst, FM, Burrell, A, Buzgau, A, Buxton, M, Charles, WN, Cove, M, Detry, MA, Estcourt, LJ, Fagbodun, EO, Fitzgerald, M, Girard, TD, Goligher, EC, Goossens, H, Haniffa, R, Hills, T, Horvat, CM, Huang, DT, Ichihara, N, Lamontagne, F, Marshall, JC, McAuley, DF, McGlothlin, A, McGuinness, SP, McVerry, BJ, Neal, MD, Nichol, AD, Parke, RL, Parker, JC, Parry-Billings, K, Peters, SEC, Reyes, LF, Rowan, KM, Saito, H, Santos, MS, Saunders, CT